02.11.2022 - ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of .
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor - read this article along with other careers information, tips and advice on BioSpace